Your browser doesn't support javascript.
loading
Immunogenicity and safety of Biological E's CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial.
Thuluva, Subhash; Paradkar, Vikram; Gunneri, SubbaReddy; Yerroju, Vijay; Mogulla, Rammohan; Suneetha, Pothakamuri Venkata; Turaga, Kishore; Kyasani, Mahesh; Manoharan, Senthil Kumar; Adabala, Srikanth; Sri Javvadi, Aditya; Medigeshi, Guruprasad; Singh, Janmejay; Shaman, Heena; Binayke, Akshay; Zaheer, Aymaan; Awasthi, Amit; Singh, Chandramani; Rao A, Venkateshwar; Basu, Indranil; Kumar, Khobragade Akash Ashok; Pandey, Anil Kumar.
Afiliación
  • Thuluva S; Clinical Development, Biological E Limited, Hyderabad, India.
  • Paradkar V; Clinical Development, Biological E Limited, Hyderabad, India.
  • Gunneri S; Clinical Development, Biological E Limited, Hyderabad, India.
  • Yerroju V; Clinical Development, Biological E Limited, Hyderabad, India.
  • Mogulla R; Clinical Development, Biological E Limited, Hyderabad, India.
  • Suneetha PV; Clinical Development, Biological E Limited, Hyderabad, India.
  • Turaga K; Clinical Development, Biological E Limited, Hyderabad, India.
  • Kyasani M; Clinical Development, Biological E Limited, Hyderabad, India.
  • Manoharan SK; Clinical Development, Biological E Limited, Hyderabad, India.
  • Adabala S; Clinical Development, Biological E Limited, Hyderabad, India.
  • Sri Javvadi A; Clinical Development, Biological E Limited, Hyderabad, India.
  • Medigeshi G; Bioassay Laboratory, Translational Health Science and Technology Institute, Faridabad, India.
  • Singh J; Bioassay Laboratory, Translational Health Science and Technology Institute, Faridabad, India.
  • Shaman H; Bioassay Laboratory, Translational Health Science and Technology Institute, Faridabad, India.
  • Binayke A; Bioassay Laboratory, Translational Health Science and Technology Institute, Faridabad, India.
  • Zaheer A; Bioassay Laboratory, Translational Health Science and Technology Institute, Faridabad, India.
  • Awasthi A; Bioassay Laboratory, Translational Health Science and Technology Institute, Faridabad, India.
  • Singh C; Department of Community and Family Medicine, All India Institute of Medical Sciences, Patna, India.
  • Rao A V; Department of General Medicine, St. Theresa's Hospital, Hyderabad, India.
  • Basu I; Department of General Medicine, Shubham Sudbhawana Hospital, Varanasi, India.
  • Kumar KAA; Department of Clinical Pharmacology, Grant Medical College & Sir J.J Hospital, Mumbai, India.
  • Pandey AK; Department of Physiology, ESIC Medical College & Hospital, Faridabad, India.
Hum Vaccin Immunother ; 19(1): 2203632, 2023 12 31.
Article en En | MEDLINE | ID: mdl-37113012
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas / COVID-19 Tipo de estudio: Clinical_trials / Observational_studies Límite: Adolescent / Adult / Aged / Aged80 / Humans / Middle aged Idioma: En Revista: Hum Vaccin Immunother Año: 2023 Tipo del documento: Article País de afiliación: India Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas / COVID-19 Tipo de estudio: Clinical_trials / Observational_studies Límite: Adolescent / Adult / Aged / Aged80 / Humans / Middle aged Idioma: En Revista: Hum Vaccin Immunother Año: 2023 Tipo del documento: Article País de afiliación: India Pais de publicación: Estados Unidos